Gepotidacin

Gepotidacin
Clinical data
Trade names	Blujepa
Other names	GSK2140944
AHFS/Drugs.com	Blujepa
License data	US DailyMed: Gepotidacin;
Routes of; administration	By mouth
ATC code	J01XX13 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;
CAS Number	1075236-89-3;
DrugBank	DB12134;
ChemSpider	34982930;
UNII	DVF0PR037D; 5P7X0H2O6B;
KEGG	D10878; D10879;
ECHA InfoCard	100.249.088
Chemical and physical data
Formula	C24H28N6O3
Molar mass	448.527 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(=O)n2c3c1ncc(=O)n3[C@@H](C2)CN4CCC(CC4)NCc5cc6c(cn5)OCCC6;
	InChI InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1; Key:PZFAZQUREQIODZ-LJQANCHMSA-N;

Gepotidacin, sold under the brand name Blujepa, is an antibiotic medication used for the treatment of urinary tract infection. Gepotidacin is a triazaacenaphthylene bacterial type II topoisomerase inhibitor. It is used as the salt gepotidacin mesylate, and is taken by mouth.

Gepotidacin was approved for medical use in the United States in March 2025.